OBJECTIVES: To investigate the activity of the hypothalamic ± pituitary ± adrenal (HPA) axis in male obesity and its relationship with several prominent parameters of the metabolic syndrome. DESIGN: A cross-sectional clinical study of the activity of the HPA axis in groups of obese males and normal-weight controls. SUBJECTS: Seventeen obese non-diabetic males with a body mass index (BMI) b 28 and eight normal-weight controls were examined. MEASUREMENTS: Fat free mass (FFM) and fat mass (FM) were measured by bioelectrical impedance, and the waistto-hip circumference ratio (WHR) was calculated in all subjects. Baseline samples were taken for sex hormone and lipid determination, and an oral glucose tolerance test (OGTT) was performed for glucose and insulin determination. The activity of the HPA axis was determined by the combined administration of human corticotropin releasing hormone (CRH) (100 m mg) and arginine vasopressin (AVP) (0.3 IU). RESULTS: As expected, FFM and FM and the WHR were higher in obese men than in controls, as were fasting insulin and stimulated (as area under the curve (AUC)) glucose and insulin concentrations. Baseline adrenocorticotropin (ACTH) and cortisol concentrations were similar in both groups, but stimulated (as AUC), ACTH was higher (P`0.05) in obese subjects than in controls, whereas no signi®cant difference in cortisol AUC was present. Since the main differences between obese subjects and controls were present during the early 30 min of the test, the correlation coef®cients between total and incremental ACTH AUC 0 ± 30 min and cortisol AUC 0 ± 30 min and all other variables were analyzed. A signi®cant correlation coef®cient was present between them and all anthropometric parameters, fasting insulin and insulin AUC , but not with androgens and gonadotrophins. In addition, a signi®cant correlation was present between total and incremental ACTH AUC 0 ± 30 min and triglyceride concentrations. However, after adjusting for BMI or FM values, all correlation coef®cients became non-signi®cant, except the one between incremental ACTH AUC 0 ± 30 min and insulin AUC (P`0.05). CONCLUSION: These ®ndings indicate that obese men may also have an altered pituitary response to combined CRHaAVP stimulation, which appears to be predominantly related to body size and total body fat. ACTH hyperresponsiveness after CRHaAVP stimulation also appears to be related to hyperinsulinaemia, but underlying mechanisms of this relationship remain to be elucidated.
Introduction
There is increasing evidence that central obesity may be associated with several abnormalities of the hypothalamic ± pituitary ± adrenal (HPA) axis, and it is suggested that these may play a role in the development of visceral fat and related metabolic alterations, including insulin resistance (IR) and hyperinsulinaemia, glucose intolerance and lipid disorders. 1 ± 3 However, the majority of available data come from studies performed in women with abdominal or visceral body fat distribution, in which exaggerated adrenocorticotropin (ACTH) and cortisol response to i.v. administration of corticotropin releasing hormone (CRH) alone 4 or combined with arginine vasopressin (AVP), 5 and higher than normal cortisol response to standard 3 or low-dose 4 i.v. ACTH stimulation or to acute mental stress challenge 6 have been found. In addition, other studies have demonstrated that these women may also show hyperactivity of the HPA axis following naloxone-induced opioid blockade, which, however, can be completely reversed by increasing serotoninergic receptor activation. 7 Taken together, these results strongly support the concept that in obese women with abdominal body fat distribution, the HPA axis may be hyperresponsive to appropriate neuroendocrine stimulations.
Studies in rats and humans have shown a greater sensitivity of the adrenals to ACTH in females than in males. 8 ± 11 This could imply that the activity of the HPA axis may have a strict dependency on gender, even in obesity. Previous studies performed in men found that the cortisol response to ACTH was signi®cantly and positively correlated with the waist-tohip ratio (WHR), after adjusting for confusing variables. 12 In addition, other authors 13 recently reported that men with elevated WHR experienced a decrease in the inhibition of cortisol secretion after submaximal dexamethasone oral administration, suggesting that blunted inhibition of the HPA axis with increasing abdominal fattening may be a contributory factor in determining increased axis activity.
There are no studies referring to the effects of speci®c releasing factors on pituitary and adrenal function in male obesity. This study was therefore carried out in obese men and appropriate normalweight controls to investigate the ACTH and cortisol response to the administration of a combined CRHa AVP stimulus, which provides a reliable physiological test for investigating pituitary ± adrenal functioning. 14 An additional aim of this study was to investigate the relationship between the activity of the HPA axis and several prominent parameters of the metabolic syndrome.
Material and methods

Subjects
This study was approved by the local ethics committee and all subjects gave informed written consent. Seventeen obese (body mass index (BMI) b 28 kga m 2 ) men and eight age-matched normal-weight controls (BMI`26), were included in the study. Their characteristics are reported in Table 1 . The obese men had been referred to the Endocrine Unit of the Department of Internal Medicine and Gastroenterology at the University of Bologna, as outpatients, for evaluation and treatment of their obesity, whereas controls were selected from doctors and volunteers on the staff. Other endocrine and metabolic diseases were excluded on the basis of physical examination and adequate laboratory tests. None of the obese subjects had diabetes. Six obese men had hypertension and ®ve had obstructive sleep apnea syndrome (OSAS), which was diagnosed by nocturnal polysomnographic examination, as previously described. 15 None took drugs for at least one month before the study, nor were any dieting. Dietary interviews, which were performed in both obese subjects and controls, demonstrated no heavy alcohol consumption ( b 30 g per day) in any subject. Four obese men, and one normal weight control, were smokers. None of the controls had a history of obesity.
Body height was measured without shoes to the nearest 0.5 cm, and body weight without clothes. The waist (W) and hip (H) circumferences were also measured, with the subjects standing, using a 1-cmwide metal measuring-tape, and their ratio (WHR) was calculated. Waist circumference was obtained as the minimum value between the iliac crest and the lateral costal margin, whereas hip circumference was determined as the maximum value over the buttocks. Bioelectrical impedance analysis (BIA) measurement was performed in all subjects using a tetrapolar-phasesensitive impedance plethysmograph (50 kHz) BIA 101S, Akern RJL System (Florence, Italy) and fat free mass (FFM) was calculated. 16 Fat mass (FM) was then calculated by subtracting FFM from body weight.
Protocol
All subjects were tested while following their usual diet, providing at least 250 g carbohydrates were ingested. Smoking was not allowed the evening before and the day on which tests were performed. Blood tests were performed in the morning (08.00 ± 08.30 h), after overnight fasting, while subjects had been quietly lying down for 15 ± 20 min. One i.v. cannula was placed in one forearm vein for blood sampling and another was placed in the contralateral arm for infusion (at the constant rate of 30 mLah) of saline (0.9% NaCl) or peptide. A single blood sample was obtained for baseline hormone concentrations in all subjects. The activity of the HPA axis was then examined by administering combined stimuli with CRH and AVP, as previously described. 4 This procedure has been shown to maximally stimulate the pituitary reserve in physiological conditions. 14 Human CRH (hCRH, Novabiochem, Laufel®ngen, 
Laboratory assays
Blood glucose concentrations were determined immediately after the OGTT, by the glucose oxidase method. Lipid determination was performed on the same day as the blood samples were taken. Total cholesterol and triglyceride were determined in plasma samples by enzymatic methods, using reagents purchased from Biochemia Boehringer Robin (Mannheim, Germany). The high-density lipoprotein (HDL) cholesterol concentration was measured after precipitation with MgCl 2 6H 2 O (0.05 mmolaL) and phosphotungstic acid (14 mmolaL) with reagents purchased from Behring (Marburg, Germany). Gonadotropin, androgen and insulin measurements were performed on plasma or serum samples stored at 720 C until assayed and determination in each man was performed in duplicate in the same assay. Insulin was measured by reagents purchased from Eiken Chemical Corporation (Tokyo, Japan). Steroids (testosterone, androstendione and dehydroepiandrosterone-sulphate-DHEA-S) were measured by RIA after serum puri®cation by ether (Carlo Erba, Milan, Italy) extraction followed by solid phase extraction on C18 disposable columns (Varian, Harbour City, CA). Extracts were reconstituted in suitable buffer, incubated overnight with antiserum and 3H-tracer (NEN Dupont, Brussel) and the separation between bound and free ligands was performed by dextran-coated charcoal. Gonadotropin LH and FSH (standard: 2nd WHO-IRP 80a552 and 94a632, respectively) levels were measured with reagents obtained from CibaCorning (Med®eld, MA) by chemiluminescent methods, and SHBG with reagents obtained from DPC (Los Angeles, CA) by a solid-phase chemiluminescent enzyme immunometric assay.
Immediately after taking the blood samples, aliquots were placed in different tubes containing EDTA with or without aprotinin (500 UamL), for cortisol and ACTH determinations, respectively, maintained in ice and then stored at 780 C until assayed. All assays of each man were performed in duplicate. ACTH was determined with an IRMA method with reagents obtained from Nichols Institute (San Juan Capistrano, CA). Sensitivity of this assay in our laboratory is approximately 1 pgamL (0.22 pmolaL). Inter-and intraassay coef®cients of variations at concentrations of 28.6 pgamL (6.3 pmolaL) and 244.3 pgamL (53.8 pmolaL) are 9.6% and 7.1%, and 7.3% and 3.7%, respectively. Cortisol was determined by RIA with reagents obtained from Diagnostic Product Corporation (Los Angeles, CA). In our laboratory, the lowest sensitivity level is 30 ngamL (8.3 nmolaL) . Inter-and intraassay coef®cients of variations at concentrations of 58 ngamL (160 nmolaL), 217 nga mL (599 nmolaL), and 359 ngamL (990 nmolaL) are 9.8%, 6.9%, 8.0% and 1.4%, 3.1%, 4.1%, respectively.
Statistics
All results are reported as mean AE standard error of the mean (S.E.M.). Inter-group comparisons were performed by the non-parametric Mann-Whitney U test, and intra-group comparisons (that is, comparison within the test for each group) were performed by the Wilcoxon rank sum test. Total and incremental ACTH and cortisol AUC after combined CRHaAVP administration were calculated by the trapezoidal method. Incremental AUC were calculated from total AUC, after subtracting for baseline area. Simple and multiple regression analysis were used as appropriate. P`0.05 was used to de®ne statistical signi®cance.
Results
Anthropometry and baseline hormones (Table 1) Other than BMI, obese men had signi®cantly higher FM, FFM, waist, hip and WHR values than controls. There were no signi®cant differences between obese subjects and controls on basal ACTH, cortisol, androstenedione, DHEA-S and gonadotropins. On the contrary, serum testosterone (P`0.01) and SHBG (P`0.01) concentrations were signi®cantly lower in obese subjects than in controls.
ACTH and cortisol response to combined CRHaAVP administration
After stimulation, ACTH and cortisol rapidly increased in control subjects, reaching peak values at 15 min (P`0.001) and 30 min P`0.001), respectively, then progressively declined to values signi®-cantly below basal levels at 120 min (P`0.05) for cortisol and at 90 min (P`0.05) and 120 min (P`0.05) for ACTH. In the obese group, there was a much more sustained and signi®cant increase of ACTH and cortisol at times 15 min (P`0.001) and 30 min (P`0.01), after which they progressively declined to values below baseline (at time 90 min, P`0.01, and 120 min, P`0.01, for ACTH, and at time 120 min, P`0.05, for cortisol). However, in obese subjects, all ACTH values from time 15 min
The hypothalamic pituitary ± adrenal axis in male obesity R Pasquali et al onwards were signi®cantly higher than in controls, whereas no signi®cant difference was present between cortisol values at any time (Figure 1 ). Total ACTH AUC was signi®cantly (P`0.005) higher in obese subjects (4200AE 382 pmolaL.min) than in controls (2313AE 283 pmolaL.min), wheras no signi®cant difference was observed in total cortisol AUC (obese subjects: 14270 AE 695 nmolaL.min vs controls: 14035AE 752 nmolaL.min). In view of the reduction of ACTH and cortisol below baseline values during the test (see above), we calculated total and incremental AUC, using hormone values at 15 min and 30 min after stimulation. Both total and incremental ACTH AUC 0 ± 30 min were signi®cantly (P`0.01) higher in obese subjects (total: 1819AE 217 pmolaL.-min, and incremental: 809AE 171 pmolaL.min, respectively) than in the control group (total: 964AE 146 pmolaL.min, and incremental: 304AE 110 pmola L.min, respectively). On the contrary, total cortisol AUC 0 ± 30 min was similar in both groups (5902AE 263 nmolaL.min vs 5633 AE 412 nmolaL.min; not statistically signi®cant (NS); incremental cortisol AUC 0 ± 30 min was higher in obese subjects (1643 AE 284 nmola L.min) than in controls (822 AE 239 nmolaL.min), but this difference was not signi®cant (0.05 b P b 0.1) (Figure 1 ).
In the obese group, there were no signi®cant effects of smoking, hypertension, OSAS, or impaired glucose tolerance on fasting and stimulated (as AUC) ACTH or cortisol concentrations.
Glucose, insulin and lipids
Fasting values of triglycerides (1.40 AE 0.10 mmola L vs 0.80AE 0.10 mmolaL, P`0.01), glucose (5.1AE 0.2 mmolaL vs 4.2 AE 0.2 mmolaL, P`0.01), and insulin (198.0 AE 31.3 mmolaL vs 36.8 AE 5.7 pmolaL, P`0.01) were signi®cantly higher in obese subjects than in controls, whereas no signi®cant difference was present in total (5.4AE 0.2 mmolaL vs 4.4 AE 0.3 mmola L) and (HDL) cholesterol (1.10 AE 0.10 mmolaL vs 1.20 AE 0.10 mmolaL) concentrations. Six obese subjects had impaired glucose tolerance, according to the World Health Organization (WHO) Expert Committee criteria. 17 Therefore, glucose AUC (P`0.05) was signi®cantly higher in obese subjects (1269AE 64 mmola L.min) than in controls (880AE 58 mmolaL.min) and, as expected, insulin AUC was signi®cantly (P`0.01) higher in the former (193.0 AE 40.7 pmolaL.min. 10 73 ) than in the latter (38.6 AE 6.2 pmolaL.min. 10 73 ).
Relationship between ACTH AUC and cortisol AUC and anthropometry, sex hormones, insulin, and lipids.
Since the main differences between obese subjects and controls were present during the early 30 min of The hypothalamic pituitary ± adrenal axis in male obesity R Pasquali et al the test, we analyzed the correlation coef®cients between total and incremental ACTH AUC0 ± 30 min , and cortisol AUC0 ± 30 min and all anthropometric and metabolic variables. A signi®cant correlation coef®cient was present between them and all anthropometric parameters (BMI, waist circumference, WHR, FFM and FM), fasting insulin and insulin AUC , but not with androgens and gonadotropins. In addition, a signi®cant correlation was present between total and incremental ACTH AUC 0 ± 30 min and triglyceride concentrations. However, after adjusting for BMI or FM values, all correlation coef®cients became non-signi®cant, except the one between incremental ACTH AUC 0 ± 30 min and insulin AUC (P`0.05) (Figure 2 ).
Discussion
The results of this study indicate that obese males may have ACTH hyper-responsiveness to combined CRHaAVP stimulation, similar to what was previously reported in women with the abdominal obesity phenotype. 4 However, this abnormality was apparently less marked than that described in such obese women. This difference between the sexes is not an unexpected ®nding, since there is evidence that females may have a greater sensitivity in the adrenals to different stimulatory neuropeptides, including ACTH. 10, 11, 18, 19 The lack of correlation between the activity of the HPA axis and anthropometric indices of body fat distribution, contrary to what was previously reported in women, 3, 5 may be explained by the fact that obesity in males is almost always associated with a parallel increase of abdominal and visceral fat, which means that the central distribution of body fat depends on the actual presence of obesity in males. This is exempli®ed by the very high correlation coef®cients between BMI and FM and waist circumference (in this study: r 0.97, P`0.0001, and r 0.89, P`0.0001, respectively) but not with the hip circumference (NS), which is commonly found in a male population. 20 Therefore, net ACTH response to CRHaAVP in obese males appears to be proportional to the increase of body size and total body fat, rather than to the amount of abdominal or visceral fat.
A further ®nding of this study was that the ACTH response was signi®cantly correlated with insulin AUC during the OGTT, regardless of BMI and FM values. The theoretical basis for this association does not necessarily imply a cause-effect relationship. However, hyperinsulinaemia represents a distinct characteristic of obesity, particularly of the visceral phenotype. However, since CRHaAVPinduced ACTH hypersecretion and increased insulin concentrations are distinct alterations simultaneously present in male obesity, it cannot be excluded that they are in some way partially related to common regulatory mechanisms. There are, in fact, conditions such as, for example, food ingestion, in which insulin and the HPA axis activity may change in the same direction, probably due to the intervention of neural factors, particularly the sympathetic nervous system, which is involved in the regulation of both insulin secretion and the HPA axis surge. 21 Recently, it has been found that ACTH and cortisol response to mixed meals may be supranormal in obese women, at least in those with the abdominal phenotype. 22 Whether altered neural-mediated mechanisms are involved in the regulation of altered HPA axis activity and in its relation with insulin secretion in obesity, either after meal ingestion or after hypothalamic or hypophyseal stimulation, remains an obscure question that needs more detailed investigation.
Conclusion
Similar to what was previously reported in women with abdominal obesity, we found that obese men may have ACTH hyperresponsiveness to combinal CRHa AVP stimulation. This alteration is closely correlated with BMI and not with parameters of body fat distribution. The independent correlation between Figure 2 Correlation coef®cient between incremental ACTH AUC 0 ± 30 min and insulin AUC-OGTT in obese and controls men (after adjusting for body mass index (BMI): t 2.1, P`0.05; after adjusting for fat mass (FM): t 2.4 P`0.05). AUC area under the curve; OGTT oral glucose tolerance test.
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